Discontinuation of statins in routine care settings

Annals of Internal Medicine

Volumn 159, Issue 1, 2013, Pages 74-75

  LeBlanc, Thomas W ^a   Kutner, Jean S ^b   Ritchie, Christine S ^c   Abernethy, Amy P ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COMORBIDITY; DRUG SAFETY; HOSPICE CARE; HUMAN; LETTER; PALLIATIVE THERAPY; POLYPHARMACY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TERMINAL CARE; HYPERCHOLESTEROLEMIA; NOTE;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84879582432     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-1-201307020-00021     Document Type: Letter

References (4)

1. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158: 526-34. [PMID: 23546564]
2. Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy [Editorial]. Ann Intern Med. 2013;158:562-3. [PMID: 23546569]
3. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648-54. [PMID: 20937924]
4. Leblanc TW, Kutner JS, Ko D, Wheeler JL, Bull J, Abernethy AP. Developing the evidence base for palliative care: formation of the palliative care research cooperative and its first trial. Hosp Pract (1995). 2010;38:137-43. [PMID: 20890063]